David Jin
CFO & Head of Corporate DevelopmentMr. David Jin is Director of Crystalys Therapeutics Inc. Mr. Jin is Director of Mustang Bio, Inc. from October 2024. Mr. Jin serves as Treasurer of Urica Therapeutics, Inc. Mr. Jin has served as Treasurer of Fortress’ private subsidiaries, including Cyprium Therapeutics, Helocyte and Cellvation. He is Interim Chief Financial Officer at Avenue Therapeutics, Inc. and serves as Chief Operating Officer since March 2022 and serves as Corporate Secretary and previously served as its Interim Principal Executive Officer from March 31, 2022 until August 01, 2022 and served as its Interim Chief Executive Officer since March 2022 until August 01, 2022 and served as its Chief Operating Officer until March 31, 2022. He serves as Chief Financial Officer at Fortress Biotech, Inc. since August 16, 2022 and serves as its Head of Corporate Development since May 2020. Previously, he was on the investment team in the Private Equity & Real Assets group at Barings. Before that, he was a Director of Corporate Development at Sorrento Therapeutics. Prior to that, he was a Vice President of Healthcare Investment Banking at FBR & Co. In his career, he was in the management consulting group at IMS Health. He holds a B.S. in Industrial Engineering & Management Sciences with a double-major in Mathematical Methods in the Social Sciences from Northwestern University.
Positions
- Company NameFortress Biotech, Inc.Stock CodeFBIOPositionCFO & Head of Corporate DevelopmentRelated Securities
- Company NameAvenue Therapeutics, Inc.Stock CodeATXIPositionInterim CFO, COO & Corporate Secretary
